GSK-backed Liquidia takes a seat at the IPO table, looking for a $57.5M stake to take on United Therapeutics
Liquidia Technologies believes the time is ripe to go public, asking investors to sign on for a $57.5 million IPO designed to get them through a late-stage study of a “new and improved” way to deliver an inhaled drug to treat pulmonary arterial hypertension — and take down United Therapeutics’ standard of care Tyvaso in the process.
The biotech — which has a technology collaboration in place with GlaxoSmithKline — has been working on perfecting its drug particle tech in developing LIQ861, an inhaled form of treprostinil. Their boast is that they know how to consistently make the well known drug in a way that can be delivered in a disposable inhaler. And that, they say, would put Tyvaso and its nebulizer — which earned $404 million last year — to shame.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.